NDAINTRAVENOUSINJECTABLE
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug Shortage Active
VAPRISOL is currently in shortage. Reason: Unavailable. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
VAPRISOL (conivaptan hydrochloride) by Cumberland Pharmaceuticals. Approved for hyponatremia. First approved in 2005.
Drug data last refreshed 19h ago
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (3)
A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
Started Feb 2012
4 enrolled
Hyponatremia
Diuretic and Renal Effects of Vaprisol When Administered Along With Furosemide and Nesiritide Continuous Infusion
Started Oct 2008
0Heart Failure
Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients
Started Aug 2008
6 enrolled
Hyponatremia
Worked on VAPRISOL at Cumberland Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.